Mustang Bio (MBIO) Cash from Financing Activities (2016 - 2026)
Mustang Bio (MBIO) posted quarterly Cash from Financing Activities of $7.1 million for Q3 2025, up 604.64% year-over-year from $1.0 million in Q3 2024, and up 3140.43% quarter-over-quarter from -$235000.0 in Q2 2025.
Mustang Bio (MBIO) Cash from Financing Activities (2016 - 2026) Analysis & Trends
Mustang Bio (MBIO) has reported Cash from Financing Activities for 10 consecutive years, with $7.1 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash from Financing Activities rose 604.64% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $6.9 million (down 63.31% YoY), while the FY2025 annual figure was $14.5 million, up 28.95% from the prior year.
- Cash from Financing Activities advanced to $7.1 million in Q3 2025 per MBIO's latest filing, from -$235000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $47.6 million in Q1 2021 and bottomed at -$30.3 million in Q2 2023.
- Historically, Cash from Financing Activities has averaged $5.8 million across 5 years, with a median of $3.6 million in 2021.
- On a YoY basis, Cash from Financing Activities climbed as much as 395500.0% in 2023 and fell as far as 1098.25% in 2023.
- Mustang Bio's Cash from Financing Activities stood at $4.9 million in 2021, then slumped by 99.98% to $1000.0 in 2022, then surged by 395500.0% to $4.0 million in 2023, then rose by 24.77% to $4.9 million in 2024, then surged by 44.75% to $7.1 million in 2025.
- Business Quant data shows MBIO's Cash from Financing Activities at $7.1 million in Q3 2025, -$235000.0 in Q2 2025, and $7.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - | -141,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -141,000.00 |
| Jun 30, 2026 | -141,000.00 |
| Sep 30, 2025 | 7.15 Mn |
| Sep 30, 2025 | 7.15 Mn |
| Jun 30, 2025 | -235,000.00 |
| Jun 30, 2025 | -235,000.00 |
| Mar 31, 2025 | 7.62 Mn |
| Mar 31, 2025 | 7.62 Mn |
| Dec 31, 2024 | 4.94 Mn |
| Dec 31, 2024 | 4.94 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 5.27 Mn |
| Jun 30, 2024 | 5.27 Mn |
| Mar 31, 2024 | 49,000.00 |
| Mar 31, 2024 | 49,000.00 |
| Dec 31, 2023 | 3.96 Mn |
| Dec 31, 2023 | 3.96 Mn |
| Sep 30, 2023 | 250,000.00 |
| Sep 30, 2023 | 250,000.00 |